EPO treatment promoted aortic dilation after 4 weeks and 7 weeks (Supplementary Fig. 12N, O), as well as aortic aneurysm (0 vs 58 %, P < 0.05) and lethal rupture (0 vs 42%, P < 0.05) (Supplementary Fig. 12P). The gene discussed is EPO; the disease is aortic aneurysm.